Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2017Antimicrobial Agents and ChemotherapyOpen Access

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMariana CastanheiraStatens Serum InstitutMHMichael D. HubandRush University Medical CenterRMRodrigo E. MendesJMI Laboratories

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Castanheira et al. (2017) studied this question.

synapsesocial.com/papers/6a7dbe14c108c8d3ff045700https://doi.org/10.1128/aac.00567-17
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World2013 · 283 citations
  2. 2Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America2008 · 5,030 citations
  3. 3Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration2012 · 75 citations
  4. 4Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City2015 · 147 citations
  5. 5Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)2013 · 203 citations